Idiopathic Pulmonary Fibrosis Mechanisms and Management

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease marked by aberrant wound-healing responses to repeated alveolar epithelial injury in genetically susceptible, ageing individuals. Dysregulated interactions between epithelial cells, fibroblasts and immune components culminate in the excessive deposition of extracellular matrix (ECM) and distortion of lung architecture. Central to disease progression are activated myofibroblasts that generate collagenous scar, persistent epithelial-mesenchymal crosstalk, altered cytokine signalling and impaired matrix turnover. Current management combines antifibrotic agents that slow functional decline, symptomatic relief measures such as cough control and supplemental oxygen, and, in advanced cases, lung transplantation. Research priorities include unravelling fibroblast heterogeneity, refining biomarkers for early diagnosis and response, optimising treatment regimens and developing novel targeted therapies to halt or reverse fibrosis.

Research from Nature Portfolio

Single-cell transcriptomic mapping has revealed discrete subsets of collagen-producing cells in normal and fibrotic lungs, identifying a CTHRC1-expressing myofibroblast population concentrated within fibroblastic foci. Functional characterisation of these cells offers a roadmap for selective targeting of the most pathogenic fibroblast subset. An artificial intelligence-driven drug discovery approach has generated a novel small-molecule inhibitor of TRAF2- and NCK-interacting kinase (TNIK) with potent anti-fibrotic and anti-inflammatory properties. This compound demonstrated efficacy in multiple organ fibrosis models via oral or inhaled administration and has cleared phase I trials for safety and pharmacokinetics, exemplifying the rapid translation from target identification to clinical candidate.

Idiopathic Pulmonary Fibrosis Mechanisms and Management publication trend

The graph below shows the total number of articles in idiopathic pulmonary fibrosis mechanisms and management across all publications each year (not limited to Nature Index journals).

Technical terms

Extracellular matrix (ECM): Network of proteins and glycoproteins providing structural support and signalling cues within lung parenchyma.

Myofibroblast: Contractile, collagen-secreting cell derived from fibroblasts or other precursors, central to scar formation.

Autophagy: Cellular degradation pathway that recycles cytoplasmic components via lysosomal processing.

TNIK: A serine/threonine kinase implicated in pro-fibrotic signalling, targetable by small-molecule inhibitors.

CTHRC1: Collagen triple helix repeat containing 1, marker of a pro-fibrotic fibroblast subset in fibrotic lungs.

Antifibrotic agents: Drugs designed to interfere with pathways driving fibrosis, notably TGF-β signalling and fibroblast activation.

References

1. Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory Research (2018).
2. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nature Communications (2020).
3. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology (2024).
4. Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K/AKT/mTOR pathway. Signal Transduction and Targeted Therapy (2024).
5. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. The Lancet Respiratory Medicine (2024).